Entrada Therapeutics IncTRDA
Price$5.68Intrinsic value$6.9122% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $4.7M-97.8% YoYTTM through 30 Jun 2026
Net Income -$165.8M-352.6% YoYTTM through 30 Jun 2026
Free Cash Flow -$135MTTM through 30 Jun 2026

Margins

Current
Operating Margin-4,834.6%
Net Margin-3,537.7%

Returns

-51.2%ROE
-49.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.89x
Net Debt-$254.9Mnet cash position
Cash & Equivalents$99.3M

Quality Metrics

Altman Z-Score-0.36
Piotroski F-Score1 / 9
FCF Margin-2,880.9%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $25.4M
Diluted EPS-$3.96TTM
'20'21'22'23'24'25
FY2025: $-3.47

Dividend

No dividend

Capital Allocation

Capex Intensity-6.9%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.